Comparable stake leader
BAKER BROS. ADVISORS LP
SEC ownership of MADRIGAL PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001157601.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
6/50
Latest evidence
06 Nov 2026
- Public ticker
- MDGL on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BAKER BROS. ADVISORS LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BAKER BROS. ADVISORS LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
06 Nov 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001157601
- Issuer location
- West Conshohocken, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of MADRIGAL PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAKER BROS. ADVISORS LP
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
6/50
Latest evidence
06 Nov 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
44 rows are not safely comparable across share classes.
13D/G row: BAKER BROS. ADVISORS LP
Showing 1-8 of 50 holder rows.
Quick read
BAKER BROS. ADVISORS LP leads the comparable SEC ownership view at 10%.
6 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAKER BROS. ADVISORS LP's linked filing trail.
Comparable ownership
Top 5
BAKER BROS. ADVISORS LP
10%
Janus Henderson Group Ltd.
8.8%
Paul A. Friedman
7.8%
Rebecca Taub
7.8%
PAULSON & CO. INC.
6.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13D/G
3/4/5
Director
|
10%
Reported 13D/G
· 06 Nov 2026
|
$1,111,268,975
2,330,144 shares
|
$0 | 06 Nov 2026 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
8.8%
Reported 13D/G
· 31 Mar 2026
|
$1,077,715,260
2,018,647 shares
|
+$231,599,280 | 31 Mar 2026 |
| Paul A. Friedman |
13D/G
3/4/5
Paul A Friedman, M.D. · Director
|
7.8%
Reported 13D/G
· 10 Dec 2025
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| Rebecca Taub |
13D/G
3/4/5
Rebecca Taub, M.D. · Director
|
7.8%
Reported 13D/G
· 10 Dec 2025
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| PAULSON & CO. INC. |
13D/G
|
6.1%
Reported 13D/G
· 31 Mar 2026
|
$743,261,329
1,392,188 shares
|
-$168,350,516 | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
|
4.6%
Reported 13D/G
· 30 Jun 2026
|
$573,111,435
1,067,346 shares
|
$0 | 30 Jun 2026 |
| BAY CITY CAPITAL LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$307,583
1,261 shares
|
— | 03 Dec 2021 |
| 667, L.P. |
3/4/5
Director
|
—
mixed-class rows
|
$809,354,888
2,042,214 shares
mixed-class rows
|
+$35,023,032 | 04 Nov 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$140,682,398.
Buys
$210,138,193
Insiders: 6
Sells
$69,455,794
Insiders: 8
Net
+$140,682,398
Shares: +419,851
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 550,836
Shares: 130,985
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 550,836 | 13,324 | $210,138,193 | $7,011,938 | +$203,126,254 |
| 3-6 | 0 | 10,068 | $0 | $5,248,951 | -$5,248,951 |
| 6-9 | 0 | 6,098 | $0 | $2,626,262 | -$2,626,262 |
| 9-12 | 0 | 101,495 | $0 | $54,568,644 | -$54,568,644 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 29 reporting-owner rows connected to MADRIGAL PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
29
Largest Forms 3/4/5 holder
667, L.P.
Net 12M change
+$140.68M
Full value: +$140,682,398 · USD · 12-month changeLatest report
06 Nov 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| 667, L.P. | Director | $809,354,888 | +$35,023,032 | +4.5% | Filing P/S | 04 Nov 2026 |
| Baker Bros. Advisors (GP) LLC | Director | $809,354,888 | +$35,023,032 | +4.5% | Filing P/S | 04 Nov 2026 |
| BAKER BROS. ADVISORS LP | Director | $809,354,888 | +$35,023,032 | +4.5% | Filing P/S | 04 Nov 2026 |
| Baker Brothers Life Sciences LP | Director | $809,354,888 | +$35,023,032 | +4.5% | Filing P/S | 04 Nov 2026 |
| Julian C. Baker | Director | $809,354,888 | +$35,023,032 | +4.5% | Filing P/S | 04 Nov 2026 |
| Felix Baker | Director | $809,354,888 | +$35,023,032 | +4.5% | Filing P/S | 04 Nov 2026 |
| Rebecca Taub | Director | $580,113,117 | -$21,675,987 | -3.6% | Mixed | 17 Jun 2026 |
| Paul A. Friedman | Director | $484,919,577 | -$26,657,462 | -5.2% | Mixed | 09 Jan 2026 |
| Fred B. Craves | Director | $122,538,572 | Mixed | 12 Mar 2025 | ||
| William John Sibold | President and CEO, Director | $108,043,806 | -$10,483,130 | -8.8% | Filing P/S | 09 Sep 2026 |
| Richard S. Levy | Director | $11,761,847 | -$2,928,716 | -20% | Mixed | 17 Jun 2026 |
| Alex G. Howarth | Chief Financial Officer | $5,741,877 | Mixed | 23 Jan 2024 | ||
| Carole Huntsman | Chief Commercial Officer | $5,482,182 | -$1,713,308 | -24% | Filing P/S | 04 Mar 2026 |
| Mardi Dier | EVP and CFO | $5,466,248 | -$3,772,798 | -41% | Filing P/S | 04 Mar 2026 |
| Brian J. Lynch | SVP and General Counsel | $5,332,092 | Mixed | 23 Jan 2024 | ||
| David Soergel | Chief Medical Officer | $4,973,759 | -$951,981 | -16% | Filing P/S | 01 Jun 2026 |
| Kelley Shannon T. | General Counsel | $4,158,800 | -$1,272,412 | -23% | Filing P/S | 06 Nov 2026 |
| Remy Sukhija | Chief Commercial Officer | $3,659,044 | Mixed | 16 Jan 2023 | ||
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | $1,995,798 | Mixed | 05 Mar 2025 | ||
| James M. Daly | Director | $1,612,811 | Mixed | 17 Jun 2026 |
Recent insider transactions for MADRIGAL PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Baker Bros. Advisors Lp | MDGL | Common Stock | Purchase | 3.88% | $29,262,431 | $384.32 | 76,140 | 2,040,682 | 06 Nov 2026 | See Footnotes |
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Purchase | 3.88% | $29,262,431 | $384.32 | 76,140 | 2,040,682 | 06 Nov 2026 | See Footnotes |
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Purchase | 3.88% | $29,262,431 | $384.32 | 76,140 | 2,040,682 | 06 Nov 2026 | See Footnotes |
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Purchase | 3.88% | $29,262,431 | $384.32 | 76,140 | 2,040,682 | 06 Nov 2026 | See Footnotes |
| Baker Bros. Advisors Lp | MDGL | Common Stock | Purchase | 3.88% | $29,262,431 | $384.32 | 76,140 | 2,040,682 | 06 Nov 2026 | See Footnotes |
| Baker Bros. Advisors Lp | MDGL | Common Stock | Purchase | 3.88% | $29,262,431 | $384.32 | 76,140 | 2,040,682 | 06 Nov 2026 | See Footnotes |
| Kelley Shannon T. | MDGL | Common Stock | Sale | -9.39% | -$430,800 | $400.00 | -1,077 | 10,397 | 06 Nov 2026 | Direct |
| Baker Bros. Advisors Lp | MDGL | Common Stock | Purchase | 0.8% | $5,760,602 | $367.71 | 15,666 | 1,964,542 | 04 Nov 2026 | See Footnotes |
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Purchase | 0.8% | $5,760,602 | $367.71 | 15,666 | 1,964,542 | 04 Nov 2026 | See Footnotes |
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Purchase | 0.8% | $5,760,602 | $367.71 | 15,666 | 1,964,542 | 04 Nov 2026 | See Footnotes |
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Purchase | 0.8% | $5,760,602 | $367.71 | 15,666 | 1,964,542 | 04 Nov 2026 | See Footnotes |
| Baker Bros. Advisors Lp | MDGL | Common Stock | Purchase | 0.8% | $5,760,602 | $367.71 | 15,666 | 1,964,542 | 04 Nov 2026 | See Footnotes |
| Baker Bros. Advisors Lp | MDGL | Common Stock | Purchase | 0.8% | $5,760,602 | $367.71 | 15,666 | 1,964,542 | 04 Nov 2026 | See Footnotes |
| William John Sibold | MDGL | Common Stock | Sale | -2.57% | -$2,831,801 | $542.39 | -5,221 | 197,746 | 11 Sep 2026 | Direct |
| William John Sibold | MDGL | Common Stock | Sale | -3.04% | -$3,407,397 | $535.59 | -6,362 | 202,967 | 09 Sep 2026 | Direct |
| Kelley Shannon T. | MDGL | Common Stock | Sale | -5.47% | -$341,940 | $514.97 | -664 | 11,474 | 17 Aug 2026 | Direct |
| John C. Reed | MDGL | Common Stock | Award | 647 | 647 | 15 Aug 2026 | Direct | |||
| John C. Reed | MDGL | Stock Option (Right to Buy) | Award | 1,078 | 1,078 | 15 Aug 2026 | Direct | |||
| William John Sibold | MDGL | Common Stock | Sale | -1.18% | -$1,368,253 | $547.30 | -2,500 | 209,329 | 20 Jul 2026 | Direct |
| William John Sibold | MDGL | Common Stock | Options Exercise | 30.9% | 50,000 | 211,829 | 17 Jul 2026 | Direct | ||
| William John Sibold | MDGL | Performance Restricted Stock Units | Options Exercise | -100% | -50,000 | 0 | 17 Jul 2026 | Direct | ||
| Rebecca Taub | MDGL | Common Stock | Award | 0.1% | 454 | 452,667 | 17 Jun 2026 | Direct | ||
| Rebecca Taub | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| Richard S. Levy | MDGL | Common Stock | Award | 2.06% | 454 | 22,469 | 17 Jun 2026 | Direct | ||
| Richard S. Levy | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| Jacqualyn A. Fouse | MDGL | Common Stock | Award | 41.4% | 454 | 1,551 | 17 Jun 2026 | Direct | ||
| Jacqualyn A. Fouse | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| James M. Daly | MDGL | Common Stock | Award | 17.3% | 454 | 3,081 | 17 Jun 2026 | Direct | ||
| James M. Daly | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| Daniel J. Brennan | MDGL | Common Stock | Award | 41.8% | 404 | 1,371 | 17 Jun 2026 | Direct | ||
| Daniel J. Brennan | MDGL | Stock Option (Right to Buy) | Award | 681 | 681 | 17 Jun 2026 | Direct | |||
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| David Soergel | MDGL | Common Stock | Sale | -9.41% | -$516,561 | $495.74 | -1,042 | 10,033 | 01 Jun 2026 | Direct |
| Richard S. Levy | MDGL | Common Stock | Sale | -20.5% | -$2,928,716 | $515.44 | -5,682 | 22,015 | 22 May 2026 | Direct |
| David Soergel | MDGL | Common Stock | Sale | -7.08% | -$435,420 | $515.90 | -844 | 11,075 | 18 May 2026 | Direct |
| Mardi Dier | MDGL | Common Stock | Sale | -13.7% | -$853,993 | $430.87 | -1,982 | 12,490 | 06 Mar 2026 | Direct |
| William John Sibold | MDGL | Common Stock | Sale | -1.02% | -$718,316 | $431.94 | -1,663 | 161,829 | 06 Mar 2026 | Direct |
| Kelley Shannon T. | MDGL | Common Stock | Sale | -2.88% | -$155,498 | $431.94 | -360 | 12,138 | 06 Mar 2026 | Direct |
| Carole Huntsman | MDGL | Common Stock | Sale | -3.2% | -$180,983 | $431.94 | -419 | 12,692 | 06 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.